share_log

Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron For Phase 1/2 Clinical Trial Evaluating SNS-101, A Conditionally Active VISTA-Blocking Antibody, in Combination With Libtayo Ij Solid Tumors

Benzinga Real-time News ·  Jan 5, 2023 07:32

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo (cemiplimab). The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo in a Phase 1/2 trial in solid tumors. Sensei is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023 pending regulatory clearance.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment